Cargando…

Effects of Pioglitazone on Asymmetric Dimethylarginine and Components of the Metabolic Syndrome in Nondiabetic Patients (EPICAMP Study): A Double-Blind, Randomized Clinical Trial

The present trial aimed to investigate the effects of pioglitazone on the serum level of asymmetric dimethylarginine (ADMA), a marker of endothelial function, and some indices of inflammation and glucose and lipid metabolism in nondiabetic metabolic syndrome patients. 104 eligible participants (57%...

Descripción completa

Detalles Bibliográficos
Autores principales: Shokouh, Pedram, Joharimoghadam, Adel, Roohafza, Hamidreza, Sadeghi, Masoumeh, Golabchi, Allahyar, Boshtam, Maryam, Sarrafzadegan, Nizal
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3654334/
https://www.ncbi.nlm.nih.gov/pubmed/23710164
http://dx.doi.org/10.1155/2013/358074
_version_ 1782269536779632640
author Shokouh, Pedram
Joharimoghadam, Adel
Roohafza, Hamidreza
Sadeghi, Masoumeh
Golabchi, Allahyar
Boshtam, Maryam
Sarrafzadegan, Nizal
author_facet Shokouh, Pedram
Joharimoghadam, Adel
Roohafza, Hamidreza
Sadeghi, Masoumeh
Golabchi, Allahyar
Boshtam, Maryam
Sarrafzadegan, Nizal
author_sort Shokouh, Pedram
collection PubMed
description The present trial aimed to investigate the effects of pioglitazone on the serum level of asymmetric dimethylarginine (ADMA), a marker of endothelial function, and some indices of inflammation and glucose and lipid metabolism in nondiabetic metabolic syndrome patients. 104 eligible participants (57% female; age between 20 and 70) were enrolled in a double-blind placebo-controlled trial and were randomized to receive either pioglitazone (uptitrated to 30 mg/day) or matching placebo for 24 weeks. Participants were clinically examined and a blood sample was obtained at baseline and at the end of the trial. Pioglitazone significantly improved C-reactive protein level irrespective of changes in insulin sensitivity. Compared with the placebo group, alanine and aspartate transaminases were decreased and high-density lipoprotein cholesterol was increased after treatment with pioglitazone. A considerably greater weight gain was also recorded in the intervention group. We failed to observe any significant changes in serum ADMA in either group and between groups with and without adjustment for age, sex, and components of the metabolic syndrome. In a nutshell, pioglitazone seems to have positive effects on lipid profile, liver transaminases, and systemic inflammation. However, its previously demonstrated endothelial function-improving properties do not seem to be mediated by ADMA.
format Online
Article
Text
id pubmed-3654334
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Hindawi Publishing Corporation
record_format MEDLINE/PubMed
spelling pubmed-36543342013-05-24 Effects of Pioglitazone on Asymmetric Dimethylarginine and Components of the Metabolic Syndrome in Nondiabetic Patients (EPICAMP Study): A Double-Blind, Randomized Clinical Trial Shokouh, Pedram Joharimoghadam, Adel Roohafza, Hamidreza Sadeghi, Masoumeh Golabchi, Allahyar Boshtam, Maryam Sarrafzadegan, Nizal PPAR Res Clinical Study The present trial aimed to investigate the effects of pioglitazone on the serum level of asymmetric dimethylarginine (ADMA), a marker of endothelial function, and some indices of inflammation and glucose and lipid metabolism in nondiabetic metabolic syndrome patients. 104 eligible participants (57% female; age between 20 and 70) were enrolled in a double-blind placebo-controlled trial and were randomized to receive either pioglitazone (uptitrated to 30 mg/day) or matching placebo for 24 weeks. Participants were clinically examined and a blood sample was obtained at baseline and at the end of the trial. Pioglitazone significantly improved C-reactive protein level irrespective of changes in insulin sensitivity. Compared with the placebo group, alanine and aspartate transaminases were decreased and high-density lipoprotein cholesterol was increased after treatment with pioglitazone. A considerably greater weight gain was also recorded in the intervention group. We failed to observe any significant changes in serum ADMA in either group and between groups with and without adjustment for age, sex, and components of the metabolic syndrome. In a nutshell, pioglitazone seems to have positive effects on lipid profile, liver transaminases, and systemic inflammation. However, its previously demonstrated endothelial function-improving properties do not seem to be mediated by ADMA. Hindawi Publishing Corporation 2013 2013-04-18 /pmc/articles/PMC3654334/ /pubmed/23710164 http://dx.doi.org/10.1155/2013/358074 Text en Copyright © 2013 Pedram Shokouh et al. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Clinical Study
Shokouh, Pedram
Joharimoghadam, Adel
Roohafza, Hamidreza
Sadeghi, Masoumeh
Golabchi, Allahyar
Boshtam, Maryam
Sarrafzadegan, Nizal
Effects of Pioglitazone on Asymmetric Dimethylarginine and Components of the Metabolic Syndrome in Nondiabetic Patients (EPICAMP Study): A Double-Blind, Randomized Clinical Trial
title Effects of Pioglitazone on Asymmetric Dimethylarginine and Components of the Metabolic Syndrome in Nondiabetic Patients (EPICAMP Study): A Double-Blind, Randomized Clinical Trial
title_full Effects of Pioglitazone on Asymmetric Dimethylarginine and Components of the Metabolic Syndrome in Nondiabetic Patients (EPICAMP Study): A Double-Blind, Randomized Clinical Trial
title_fullStr Effects of Pioglitazone on Asymmetric Dimethylarginine and Components of the Metabolic Syndrome in Nondiabetic Patients (EPICAMP Study): A Double-Blind, Randomized Clinical Trial
title_full_unstemmed Effects of Pioglitazone on Asymmetric Dimethylarginine and Components of the Metabolic Syndrome in Nondiabetic Patients (EPICAMP Study): A Double-Blind, Randomized Clinical Trial
title_short Effects of Pioglitazone on Asymmetric Dimethylarginine and Components of the Metabolic Syndrome in Nondiabetic Patients (EPICAMP Study): A Double-Blind, Randomized Clinical Trial
title_sort effects of pioglitazone on asymmetric dimethylarginine and components of the metabolic syndrome in nondiabetic patients (epicamp study): a double-blind, randomized clinical trial
topic Clinical Study
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3654334/
https://www.ncbi.nlm.nih.gov/pubmed/23710164
http://dx.doi.org/10.1155/2013/358074
work_keys_str_mv AT shokouhpedram effectsofpioglitazoneonasymmetricdimethylarginineandcomponentsofthemetabolicsyndromeinnondiabeticpatientsepicampstudyadoubleblindrandomizedclinicaltrial
AT joharimoghadamadel effectsofpioglitazoneonasymmetricdimethylarginineandcomponentsofthemetabolicsyndromeinnondiabeticpatientsepicampstudyadoubleblindrandomizedclinicaltrial
AT roohafzahamidreza effectsofpioglitazoneonasymmetricdimethylarginineandcomponentsofthemetabolicsyndromeinnondiabeticpatientsepicampstudyadoubleblindrandomizedclinicaltrial
AT sadeghimasoumeh effectsofpioglitazoneonasymmetricdimethylarginineandcomponentsofthemetabolicsyndromeinnondiabeticpatientsepicampstudyadoubleblindrandomizedclinicaltrial
AT golabchiallahyar effectsofpioglitazoneonasymmetricdimethylarginineandcomponentsofthemetabolicsyndromeinnondiabeticpatientsepicampstudyadoubleblindrandomizedclinicaltrial
AT boshtammaryam effectsofpioglitazoneonasymmetricdimethylarginineandcomponentsofthemetabolicsyndromeinnondiabeticpatientsepicampstudyadoubleblindrandomizedclinicaltrial
AT sarrafzadegannizal effectsofpioglitazoneonasymmetricdimethylarginineandcomponentsofthemetabolicsyndromeinnondiabeticpatientsepicampstudyadoubleblindrandomizedclinicaltrial